Inozyme Pharma Inc expected to post a loss of 44 cents a share - Earnings Preview

Inozyme Pharma

01/11/2024 14:52

* Inozyme Pharma Inc  INZY.OQ   INZY.O  is expected to show
no
change in quarterly revenue when it reports  results on November
5 (estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Inozyme Pharma Inc is
for a
loss of 44 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Inozyme
Pharma
Inc is 15.50​, above​ its last closing price of $4.29. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.39       -0.39      -0.44     Missed  -13
 Mar. 31 0001  -0.36       -0.36      -0.38     Missed  -5.6
 Dec. 31 2023  -0.34       -0.32      -0.33     Missed  -3.6​
 Sep. 30 2023  -0.31       -0.32      -0.29     Beat    8.3
 ​​Jun.        -0.40       -0.43      -0.35     Beat    19.2
 30 2023                                                
 Mar. 31 2023  -0.44       -0.45      -0.40     Beat    10.3​
 Dec. 31 2022  -0.42       -0.45      -0.42     Beat    7
 Sep. 30 2022  -0.43       -0.43      -0.38     Beat    12.5
 This summary was machine generated November 1 at 14:52 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)